



# Minutes

**BRI Institutional Biosafety Committee  
Institutional Biosafety Committee  
2/10/2026  
1:00 pm  
Zoom**

## 1 Statements of Confidentiality and Conflicts of Interest

**Quorum and Meeting Access:** The Chair called the meeting to order at 1:00 pm and noted that the meeting was open to the public. Quorum existed at the start of the meeting with 11 voting members present. A quorum was maintained for the entire meeting.

**Confidentiality:** The Chair reminded the committee that while the meeting is open to the public, the information discussed during the meeting should be treated as confidential.

**Conflict of Interest:** The Chair asked the committee if any members needed to declare a conflict of interest with respect to any matter on the agenda. The Chair notified committee members that if they had a conflict of interest, they must leave the room during the final discussion and voting on that IBC submission.

## 2 Attendees

### Committee Members Present

Lewis Bowen (Campus Operations)	Biological Safety Officer
Lezi E (Cell Biology Neurobiology and Anatomy)	R/SNA Technology Expert
Benjamin Gantner (Medicine)	Chair
Kunal Gupta (Neurosurgery)	R/SNA Technology Expert
Anna Huppler (Pediatrics)	R/SNA Technology Expert
Eric Jensen (Research Office)	Animal Containment Expert
Tyce Kearl (Medicine)	R/SNA Technology Expert HGT Expert
Angela Mathison (Surgery)	R/SNA Technology Expert
Sandy Montes-Gruber (Non-MCW)	Non-Affiliated Member
Qizhen Shi (Pediatrics)	R/SNA Technology Expert
Matthew Surdel (Medicine)	R/SNA Technology Expert

### Committee Members Absent

Kenneth Allen (Research Office)	Alternate Animal Containment Expert, Non-Voting
---------------------------------	--

James Case (Non-MCW)  
 Nikki Lytle (Surgery)  
 Laura Stephens (Non-MCW)

Non-Affiliated Member  
 R/SNA Technology Expert  
 Non-Affiliated Member

---

### 3 Meeting Minutes Reviewed at this Meeting

---

1/13/2026 (Zoom)

<b>Motion:</b>	Minutes Approved
<b>Yes Votes:</b>	11
<b>No Votes:</b>	0
<b>Abstained:</b>	0
<b>Recused:</b>	0
<b>Total Votes:</b>	11

---

### 4 New Business

#### 1. BSL2+ PPE Requirements

The Chair and the Biological Safety Officer informed the Institutional Biosafety Committee (IBC) that tissue culture spaces are shared between multiple labs in the new Center for Cancer Discovery (CCD) building. A lab performing work requiring biological safety level (BSL)2+ containment (such as with oncogenic lentiviral vectors) could be working in a biosafety cabinet (BSC) right next to a lab performing standard BSL2 tissue culture. The concern with this arrangement is that staff only working with BSL2 agents do not have or use respirators. The Biosafety Office evaluated the situation and recommended that work with BSL2+ agents in the CCD can be done without respirators as long as that work is confined to BSCs. All other personal protective equipment (i.e. double gloves, dedicated lab coat (either a cuffed lab coat or a standard lab coat with sleeve protectors for added skin protection), and surgical mask or face shield) would still be required, and PIs would need to submit an amendment to their IBC application to reflect this change. The Chair made a motion to remove the respirator requirement for BSL2+ work in the CCD. The motion was seconded, and the Committee voted to approve this change for the CCD location.

#### 2. Administrative Report

The Chair asked the Committee Members to review the Administrative Report and then invited discussion. No concerns were raised.

#### 3. Exempt Rodent Report

The Exempt Rodent Report was provided to the Committee members.

---

### 5 Application Reviews

---

#### IBC20240087\_AME02 *Interventional genomics*

Principal Investigator:	Phillip Doerfler
<b>Motion:</b>	Decision Pending Changes
<b>Yes Votes:</b>	11
<b>No Votes:</b>	0
<b>Abstained:</b>	0
<b>Recused:</b>	0
<b>Total Votes:</b>	11

**NIH Guidelines:** Section III-D-1, Section III-D-2, Section III-D-3, Section III-D-4, Section III-E, Section III-F-1, Section III-F-8 (C-I), Section

**5****Application Reviews**

III-F-8 (C-II)

**Biosafety Level(s):** BSL1, BSL2**Deliberations:**

The Chair introduced this new Institutional Biosafety Committee (IBC) application, allowing the Primary Reviewer to describe the study. The Principal Investigator (PI) would like to produce third generation lentiviral vectors in his lab. The lab uses lentiviral vectors to deplete or overexpress various genes to study their effects on multiple biological processes. The Committee confirmed that all personnel listed in the application completed safety training appropriate for work with the materials described. The Primary and Secondary Reviewers requested several changes to clarify how these vectors will be used, what cells will be used to create the vectors, and where the vectors will be stored. The Biological Safety Officer (BSO) had no additional concerns. After brief discussion, upon a motion duly made by the Primary Reviewer and seconded, the Committee voted to approve this application pending the requested changes.

**IBC20200005\_REN02** **Role of chromatin dynamics in normal and leukemic hematopoiesis**

Principal Investigator: John Pulikkan

**Motion:** Decision Pending Changes**Yes Votes:** 11**No Votes:** 0**Abstained:** 0**Recused:** 0**Total Votes:** 11**NIH Guidelines:** Section III-D-1, Section III-D-2, Section III-D-3, Section III-D-4, Section III-E, Section III-F-8 (C-I), Section III-F-8 (C-II)**Biosafety Level(s):** BSL1, BSL2, BSL2+**Deliberations:**

The Chair introduced this renewal of an Institutional Biosafety Committee (IBC) application, and the Secondary Reviewer went on to explain the study. The Principal Investigator (PI) studies the deregulation of the transcription factor C/EBPa (a master regulator of granulopoiesis) and the core-binding factor (CBF) complex (RUNX and CBF $\beta$ ) in acute myeloid leukemia (AML) using genetic (conditional knock-in) and patient-derived xenograft (PDX) models. Murine Stem Cell Virus (MSCV) and lentivirus will be used to introduce oncogenes into primary mouse or human bone marrow cells. Clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 genome editing will be used to manipulate CEBPA mutants to investigate their roles in leukemia development. The Committee confirmed that all personnel listed in the application completed safety training appropriate for work with the materials described. The Primary and Secondary Reviewers stated the protocol is well written, and the risk assessments and mitigation strategies are appropriate. The Primary and Secondary Reviewers requested that the PI confirm locations where biological materials will be used, clarify whether lentiviral vectors will be used for CRISPR, and describe how biological materials will be packaged for onsite transport. The Biological Safety Officer (BSO) requested that the PI to use the drop-down menu to update the MSCV entry. The Animal Containment Expert (ACE) had no additional concerns. Upon a motion duly made by the Primary Reviewer and seconded, the Committee voted to approve this renewal pending the requested changes.

**6****Adjournment**

There being no further business, the meeting was adjourned at 2:02 pm. The next regularly scheduled meeting will be held on Tuesday, March 10, 2026 at 1:00 pm in Zoom.